Ferguson Wellman Capital Management Inc. Sells 533 Shares of Stryker Co. (NYSE:SYK)

Ferguson Wellman Capital Management Inc. lessened its stake in shares of Stryker Co. (NYSE:SYK) by 0.3% during the 4th quarter, Holdings Channel reports. The fund owned 171,530 shares of the medical technology company’s stock after selling 533 shares during the period. Stryker comprises approximately 1.2% of Ferguson Wellman Capital Management Inc.’s holdings, making the stock its 24th largest position. Ferguson Wellman Capital Management Inc.’s holdings in Stryker were worth $61,759,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SYK. Ritholtz Wealth Management lifted its holdings in shares of Stryker by 6.3% during the 3rd quarter. Ritholtz Wealth Management now owns 5,140 shares of the medical technology company’s stock valued at $1,857,000 after purchasing an additional 306 shares during the last quarter. InTrack Investment Management Inc boosted its stake in Stryker by 8.1% in the 3rd quarter. InTrack Investment Management Inc now owns 3,612 shares of the medical technology company’s stock worth $1,305,000 after purchasing an additional 271 shares in the last quarter. Mechanics Bank Trust Department boosted its stake in Stryker by 5.0% in the 3rd quarter. Mechanics Bank Trust Department now owns 7,563 shares of the medical technology company’s stock worth $2,732,000 after purchasing an additional 359 shares in the last quarter. Annex Advisory Services LLC grew its position in Stryker by 6.0% during the 3rd quarter. Annex Advisory Services LLC now owns 8,314 shares of the medical technology company’s stock worth $3,004,000 after purchasing an additional 471 shares during the last quarter. Finally, Retirement Planning Group LLC acquired a new position in Stryker during the 3rd quarter valued at approximately $249,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 1.2 %

Shares of NYSE SYK opened at $391.42 on Monday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $377.23 and a 200 day moving average of $364.97. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The stock has a market cap of $149.22 billion, a PE ratio of 50.44, a P/E/G ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the firm posted $3.46 earnings per share. As a group, sell-side analysts predict that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on SYK shares. Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. BTIG Research boosted their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Barclays raised their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Finally, Robert W. Baird upped their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.